Here’s why Moderna’s coronavirus vaccine could outsell Pfizer’s

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

If you could get a coronavirus inoculation this afternoon, you probably wouldn’t care if the clinician told you that the shot might feel a bit chilly. But when it comes to hiring employees or judging which vaccine is going to sell better, it pays to know the difference between candidates that don’t need special help to keep their cool and those that need to be beyond ice-cold to have a chance at success. 

Will Moderna Inc‘s (NASDAQ: MRNA) newly proven vaccine outperform its competitor made by Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), which is likely to obtain regulatory approval and subsequently hit the market…